Author
Kim Whitley
Scientific Content Manager
Kirsty Maclean, Global Head of R&D; Sushant Dusange, Business Development Senior Director; and Wendy Laird, Business Development Director, represented Cerba Research at the summit, joining bioanalytical scientists, assay development experts, and pharmaceutical sponsors to discuss the latest advances shaping immunogenicity assessment, bioassay development, and translational science.
Conversations across gene therapy, immune modulation, RNA therapeutics, and antibody-based treatments reflected a field facing evolving analytical requirements – and looking for better ways to accelerate drug development.
Read on for a closer look at the key discussions and what they mean for sponsors planning complex programs.
One theme stood out across the presentations and posters: emerging evidence of sex-related differences in immune responses to adeno-associated virus (AAV) vectors.
Leila Abdelhamid, Biomedical Scientist from the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), presented “Unveiling Sex Bias in AAV Vector Responses: From Pre-existing Antibodies to Innate Immunogenicity.” Her presentation highlighted evidence that females can show stronger immune responses to AAV vectors, which may affect both the safety and efficacy of treatment.
The findings build on a 2025 study from the laboratory of Ronit Mazor, Principal Investigator and Gene Therapy Regulator at the FDA. The researchers found that female serum samples had significantly higher levels of pre-existing antibodies and greater transduction-inhibiting activity across multiple therapeutic AAV serotypes.
This has implications for clinical development, particularly patient screening, eligibility criteria, and trial design. Accounting for pre-existing immunity and sex-related differences in AAV vector responses can support a more accurate immunogenicity assessment and clearer interpretation of treatment outcomes.
Another area of interest was the potential to modify or retrain immune responses to address autoimmune disorders, severe allergies, and other immune-mediated conditions.
Amy Rosenberg, Senior Director, Bioanalytical Sciences at Regeneron Pharmaceuticals, explored this topic in her presentation, “Immune Reset: Addressing Autoimmune Disease, Allergy, and Novel Indications,” which was also the focus of a wider panel discussion. The session examined emerging therapeutic approaches designed to promote immune tolerance and reduce harmful immune responses.
One highlight was the use of computational screening tools and artificial intelligence (AI) to identify specialized sequences within human immunoglobulins known as Tregitopes. Researchers are exploring whether these sequences, when incorporated into protein therapies or other complex therapeutics, can recruit regulatory T cells (Tregs), which help control immune responses. This approach could offer new ways to address allergic reactions, drug hypersensitivities, and autoimmune activity.
Therapies designed to reshape immune responses need assays that show whether, and how, that response is changing. Planning that assay strategy early can help keep development on track, from first-in-human through late-stage development.
Several presentations explored the expanding use of RNA-based approaches, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA), across a range of disease areas.
Each modality offers a different mechanism for targeting and modifying biological processes, and each brings additional considerations for safety assessment and immunogenicity. Discussions touched on potential interactions with the immune system, alongside the manufacturing and regulatory challenges of developing and characterizing these therapies.
As the range of RNA-based treatments grows, robust bioanalytical strategies will be important for evaluating activity, safety, and performance throughout development.
Antibody-drug conjugates (ADCs) also featured. In her presentation, “Navigating Pre-Existing Anti-Drug Antibodies in Complex Modalities: Mechanisms, Bioanalytical Challenges, and Clinical Impact,” Nellie Moshkovich, Associate Director, Clinical Pharmacology at AstraZeneca, explored the immunogenicity challenges tied to ADC design, including the potential contributions of the antibody backbone, the cytotoxic payload, and the linker. More broadly, the impact of anti-drug antibodies (ADAs) on pharmacokinetics, efficacy, and safety remains a key consideration for ADCs and other antibody-based therapeutics.
The discussions reinforced the need to consider immunogenicity across every component of a complex antibody-based therapeutic, rather than focusing solely on the antibody itself.
For a closer look at how tailored assay strategies address this, watch our on-demand webinar, Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs.
Across the summit, discussions focused heavily on assay design, development challenges, validation strategies, and bioanalytical decision-making.
The scientific sessions showed how emerging modalities are raising new questions about immune responses, patient variability, and the assessment of safety and efficacy. Answering them requires analytical approaches that reflect the characteristics of each therapeutic and its intended mechanism of action.
For sponsors, this places continued emphasis on fit-for-purpose assay development and validation that can support complex programs from early development through clinical evaluation.
The themes at the Immunogenicity & Bioassay Summit 2026 point to a field where the questions are becoming more specific – and where the analytical answers need to keep pace.
Advances in gene therapy, immune modulation, RNA therapeutics, and antibody-based treatments are expanding what drug developers need to understand. From sex-related differences in AAV immune responses to immunogenicity across increasingly complex designs, generating meaningful data depends on specialized analytical approaches, supported by scientific input that connects each assay strategy to the needs of the program.
For us, the summit reinforced the value of scientific partnership, technical expertise, and staying closely aligned with the evolving requirements of complex therapeutic development.
Planning immunogenicity or bioanalytical testing for a complex therapeutic? Talk to our team about building a fit-for-purpose strategy that supports your program from early development through to clinic.